Gynecologic Oncology

The combination of nivolumab plus ipilimumab was found to induce a superior response rate and longer progression-free survival compared with nivolumab alone in patients with persistent or recurrent epithelial ovarian cancer.

Konstantin Zakashansky, MD, gynecologic oncologist and associate professor of Obstetrics, Gynecology and Reproductive Science at Mount Sinai Health System, discusses repeat exposure to PARP inhibition in patients with platinum-sensitive, relapsed ovarian cancer.

Joyce F. Liu, MD, MPH, discusses findings from a phase 2 study with the Wee1 inhibitor adavosertib in patients with recurrent uterine serous carcinoma.

Gestational trophoblastic tumors (GTTs) that resist chemotherapy can be treated with frontline avelumab, making avelumab the first immunotherapy to show efficacy in treating patients with GTT, according to findings from a cohort of the ongoing phase 2 TROPHIMMUN trial.

Maintenance niraparib improved progression-free survival in Chinese patients with recurrent ovarian cancer who were in a complete or partial response to platinum-based chemotherapy, meeting the primary end point of the phase 3 NORA study.

Brian M. Slomovitz, MD, explaines the need to determine optimal sequencing strategies in endometrial cancer.

Brian M. Slomovitz, MD, explaines the need to determine optimal sequencing strategies in endometrial cancer.

Shannon N. Westin, MD, MPH, discusses novel targets in endometrial cancer.

Thomas Herzog, MD, discusses the FDA approval of olaparib plus bevacizumab for the frontline maintenance treatment of patients with homologous recombination deficiency–positive ovarian cancer.

The anti­–folate receptor alpha antibody-drug conjugate STRO-002 showed early clinical promise in patients with advanced ovarian cancer.

The vaccine BVAC-C demonstrated durable antitumor activity in patients recurrent cervical cancer.

Shannon N. Westin, MD, MPH, FACOG, discusses future directions in endometrial cancer.

Ritu Salani, MD, discusses the evolving role of biomarker development and testing in cervical cancer.

A reduction in patient-reported symptomatic adverse events was observed with intensity-modulated radiotherapy compared with standard radiotherapy in patients with cervical or endometrial cancer, whereas no difference was observed with regard to clinician-reported AEs.

Robert L. Coleman, MD, FACOG, FACS, discusses recent advancements made in the cervical cancer space.

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses data with STRO-002 in patients with platinum-resistant/refractory ovarian cancer.

The FDA has approved niraparib for use as a frontline maintenance treatment for women with advanced ovarian cancer who responded to platinum-based chemotherapy.

Amanda Nickles Fader, MD, discusses the rationale for a phase II study and explains how the findings could open the door to other treatment options for women with uterine serous carcinoma.

The PD-1 inhibitor dostarlimab demonstrated clinically meaningful activity in patients with mismatch repair–deficient endometrial cancer.

Bhavana Pothuri, MD, discusses the importance of obtaining patient-reported outcomes in ovarian cancer.

Amanda Nickles Fader, MD, discusses the utility of trastuzumab plus chemotherapy in HER2-positive uterine serous carcinoma.

We recently traveled to Columbus, Ohio for a State of the Science Summit™ on Ovarian Cancer, which featured insights from The Ohio State University Comprehensive Cancer Center–James faculty.

Elizabeth M. Swisher, MD, discusses the limitations of homologous recombination deficiency as a biomarker of response in ovarian cancer based on findings from the phase III VELIA trial.

The cobas HPV test for cervical cancer screening is now FDA-approved for use on the high-throughput cobas 6800/8800 Systems.

The China National Medical Products Administration has granted a priority review to niraparib for use as a frontline maintenance treatment for adult patients with advanced ovarian cancer.